Artiva Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Artiva Biotherapeutics, Common
ARTV Stock   10.40  0.22  2.07%   
Artiva Biotherapeutics, financial statements provide useful quarterly and yearly information to potential Artiva Biotherapeutics, Common investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Artiva Biotherapeutics, financial statements helps investors assess Artiva Biotherapeutics,'s valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Artiva Biotherapeutics,'s valuation are summarized below:
Market Capitalization
252.6 M
Enterprise Value Revenue
46.4998
Revenue
2.6 M
Earnings Share
(2.48)
Quarterly Revenue Growth
(0.75)
There are over one hundred one available fundamental signals for Artiva Biotherapeutics, Common, which can be analyzed over time and compared to other ratios. All traders should should validate Artiva Biotherapeutics,'s prevailing fundamental trends against the trends from 2010 to 2024 to make sure the company is sustainable.

Artiva Biotherapeutics, Total Revenue

35.17 Million

Check Artiva Biotherapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Artiva Biotherapeutics,'s main balance sheet or income statement drivers, such as Net Interest Income of 2.7 M, Interest Income of 2.7 M or Depreciation And Amortization of 2.4 M, as well as many indicators such as Price To Sales Ratio of 3.18, Dividend Yield of 0.0 or Days Sales Outstanding of 18.2. Artiva financial statements analysis is a perfect complement when working with Artiva Biotherapeutics, Valuation or Volatility modules.
  
Check out the analysis of Artiva Biotherapeutics, Correlation against competitors.

Artiva Biotherapeutics, Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Long Term Debt4.5 M5.1 M5.5 M
Slightly volatile
Total Assets120.3 M105.1 M56.7 M
Slightly volatile
Short and Long Term Debt Total11.1 M16.9 M4.8 M
Slightly volatile
Other Current Liabilities8.7 M8 M4.8 M
Slightly volatile
Total Current Liabilities17.3 M12.2 M9.2 M
Slightly volatile
Property Plant And Equipment Net16.1 M24.6 M6.6 M
Slightly volatile
Accounts Payable1.1 M614 K1.9 M
Slightly volatile
Cash94.2 M53.5 M46.1 M
Slightly volatile
Non Current Assets Total17.7 M25.3 M7.6 M
Slightly volatile
Non Currrent Assets Other1.1 M650 K944.4 K
Slightly volatile
Cash And Short Term Investments100.6 M77 M48.1 M
Slightly volatile
Common Stock Shares Outstanding12.4 M9.4 M16.7 M
Slightly volatile
Liabilities And Stockholders Equity120.3 M105.1 M56.7 M
Slightly volatile
Non Current Liabilities Total216.6 M254.9 M97 M
Slightly volatile
Capital Lease Obligations11.1 M16.9 M4.8 M
Slightly volatile
Other Current Assets1.2 M1.1 M807.2 K
Slightly volatile
Other Stockholder Equity10 M19 M3.4 M
Slightly volatile
Total Liabilities233.9 M267.1 M106.2 M
Slightly volatile
Property Plant And Equipment Gross17.6 M28.2 M7.1 M
Slightly volatile
Total Current Assets102.5 M79.8 M49.1 M
Slightly volatile
Non Current Liabilities Other80 K73 K119.3 K
Slightly volatile
Net Working Capital85.2 M67.6 M39.9 M
Slightly volatile
Short Term Debt2.2 M3.6 M983 K
Slightly volatile
Current Deferred Revenue10 M12.5 M8.1 M
Slightly volatile
Other Assets4 K4.5 K4.9 K
Slightly volatile
Accumulated Other Comprehensive Income246.4 K277.2 K301.8 K
Slightly volatile

Artiva Biotherapeutics, Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization2.4 M2.3 M457 K
Slightly volatile
Selling General Administrative14.3 M13.9 M7.4 M
Slightly volatile
Other Operating Expenses55.7 M64.2 M29.4 M
Slightly volatile
Research Development41.4 M50.3 M22 M
Slightly volatile
Total Operating Expenses55.7 M64.2 M29.4 M
Slightly volatile
Reconciled Depreciation2.4 M2.3 M457 K
Slightly volatile
Gross Profit35.2 M33.5 M6.5 M
Slightly volatile
Tax Provision68.8 K72 K55.3 K
Slightly volatile

Artiva Biotherapeutics, Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation5 M7.1 M1.7 M
Slightly volatile
Begin Period Cash Flow80.1 M102.8 M26 M
Slightly volatile
Depreciation2.4 M2.3 M457 K
Slightly volatile
Capital Expenditures3.2 M3.3 M1.2 M
Slightly volatile
Issuance Of Capital Stock104.2 M177.8 M65 M
Slightly volatile
End Period Cash Flow94.4 M53.8 M46.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.183.351787.6035
Slightly volatile
Days Sales Outstanding18.219.158973.3411
Slightly volatile
Stock Based Compensation To Revenue0.20.21061.8375
Slightly volatile
Capex To Depreciation1.371.43783.8662
Pretty Stable
EV To Sales2.152.259122.7296
Slightly volatile
ROIC0.180.18980.7273
Slightly volatile
Sales General And Administrative To Revenue0.390.41545.475
Slightly volatile
Research And Ddevelopement To Revenue1.431.500417.7371
Slightly volatile
Capex To Revenue0.09240.09730.7867
Slightly volatile
Cash Per Share4.938.22822.9372
Slightly volatile
Income Quality1.731.65150.8492
Slightly volatile
ROE0.160.17090.7154
Slightly volatile
Net Debt To EBITDA1.721.28821.4086
Slightly volatile
Current Ratio4.716.52834.9036
Slightly volatile
Receivables Turnover20.019.05126.6518
Slightly volatile
Graham Number17.0633.966810.3655
Slightly volatile
Capex Per Share0.370.34830.0901
Slightly volatile
Revenue Per Share3.763.58030.5991
Slightly volatile
Interest Debt Per Share0.0090.01020.0111
Slightly volatile
Ebt Per Ebit1.160.90071.0144
Slightly volatile
Quick Ratio4.716.52834.9036
Slightly volatile
Net Income Per E B T0.81.00260.9876
Slightly volatile
Cash Ratio5.814.37594.7384
Slightly volatile
Days Of Sales Outstanding18.219.158973.3411
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.861.06871.0264
Very volatile
Fixed Asset Turnover1.431.35910.5906
Slightly volatile
Price Sales Ratio3.183.351787.6035
Slightly volatile
Asset Turnover0.330.31860.0551
Slightly volatile
Return On Equity0.160.17090.7154
Slightly volatile

Artiva Fundamental Market Drivers

Cash And Short Term Investments77 M

About Artiva Biotherapeutics, Financial Statements

Artiva Biotherapeutics, investors use historical fundamental indicators, such as Artiva Biotherapeutics,'s revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Artiva Biotherapeutics,. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue12.5 M10 M
Total Revenue33.5 M35.2 M
Stock Based Compensation To Revenue 0.21  0.20 
Sales General And Administrative To Revenue 0.42  0.39 
Research And Ddevelopement To Revenue 1.50  1.43 
Capex To Revenue 0.10  0.09 
Revenue Per Share 3.58  3.76 
Ebit Per Revenue(0.92)(0.96)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Artiva Stock Analysis

When running Artiva Biotherapeutics,'s price analysis, check to measure Artiva Biotherapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artiva Biotherapeutics, is operating at the current time. Most of Artiva Biotherapeutics,'s value examination focuses on studying past and present price action to predict the probability of Artiva Biotherapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Artiva Biotherapeutics,'s price. Additionally, you may evaluate how the addition of Artiva Biotherapeutics, to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY